Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Celcuity Inc. - Common Stock (NQ:CELC)

77.52 +3.52 (+4.76%)
Streaming Delayed Price Updated: 10:48 AM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Celcuity Inc. - Common Stock

< Previous 1 2 Next >
Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 Billion
EQNX::TICKER_START (NASDAQ:GTBP),(NASDAQ:LPTX),(NASDAQ:IOBT),(NASDAQ:CELC),(NYSE:MAIA) EQNX::TICKER_END 
Via FinancialNewsMedia
Peraso (NASDAQ: PRSO) Powers Military, Nex-Gen Broadband Surge – Mag 7 Undercard VAPE CELC, CRVO – More Stocks Inside
Via AB Newswire
Topics Supply Chain
Celcuity Inc. Announces $50 Million Private Placement
Via ACCESSWIRE
Celcuity Appoints Polly Murphy, D.V.M., Ph.D., to Board of Directors
Via ACCESSWIRE
Celcuity Set to Join Russell 2000 and 3000 Indexes
Via ACCESSWIRE
Celcuity to Participate in Upcoming Craig-Hallum and Jefferies Investor Conferences
Via ACCESSWIRE
Celcuity Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Updates
Via ACCESSWIRE
Celcuity Presents Updated Results from Phase 1b Study of Gedatolisib in Treatment-Naïve Patients at the 2023 ESMO Breast Cancer Annual Congress
Via ACCESSWIRE
Celcuity Inc. Schedules Release of First Quarter 2023 Financial Results and Webcast/Conference Call
Via ACCESSWIRE
Celcuity to Present Updated Results for Treatment-Naïve Patients from Phase 1b Study of Gedatolisib at the 2023 ESMO Breast Cancer Annual Congress
Via ACCESSWIRE
Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Gynecological Cancer Models at AACR Annual Meeting 2023
Via ACCESSWIRE
Celcuity to Participate in 22nd Annual Needham Virtual Healthcare Conference
Via ACCESSWIRE
Celcuity Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Via ACCESSWIRE
Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2022 Financial Results and Webcast/Conference Call
Via ACCESSWIRE
Celcuity to Present Preclinical Data on Therapeutic Effects of Gedatolisib in Gynecological Cancer Models at AACR Annual Meeting 2023
Via ACCESSWIRE
Celcuity to Participate in Cowen's 43rd Annual Health Care Conference
Via ACCESSWIRE
Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Prostate Cancer at ASCO GU Cancers Symposium
Via ACCESSWIRE
Celcuity Closes $100 Million Private Placement
Via ACCESSWIRE
Celcuity Presents Updated Results of Phase 1b Study of Gedatolisib in Patients with Advanced Breast Cancer at the 2022 San Antonio Breast Cancer Symposium
Via ACCESSWIRE
Celcuity Announces First Patient Dosed in Phase 3 VIKTORIA-1 Clinical Trial of Gedatolisib for the Treatment of HR+/HER2- Advanced Breast Cancer
Via ACCESSWIRE
Celcuity to Present Additional Data for Gedatolisib at the 2022 San Antonio Breast Cancer Symposium
Via ACCESSWIRE
Celcuity to Participate in the 13th Annual Craig-Hallum Alpha Select Conference
Via ACCESSWIRE
Celcuity Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Via ACCESSWIRE
Celcuity Inc. Schedules Release of Third Quarter 2022 Financial Results and Webcast/Conference Call
Via ACCESSWIRE
Celcuity Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Via ACCESSWIRE
Celcuity Inc. Schedules Release of Second Quarter 2022 Financial Results and Webcast/Conference Call
Via ACCESSWIRE
Celcuity to Participate in the Canaccord Genuity 42nd Annual Growth Conference
Via ACCESSWIRE
Celcuity Announces FDA Breakthrough Therapy Designation for Gedatolisib for Treatment of HR+/HER2- Metastatic Breast Cancer
MINNEAPOLIS, MN / ACCESSWIRE / July 18, 2022 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for hormonally driven cancers, today... 
From Celcuity Inc.
Via AccessWire
Celcuity to Participate in Upcoming Craig-Hallum and Jefferies Investor Conferences
MINNEAPOLIS, MN / ACCESSWIRE / May 26, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating... 
From Celcuity Inc.
Via AccessWire
Celcuity Inc. Reports First Quarter 2022 Financial Results and Business Updates
- Entered into $100 Million Private Placement Agreement - Finalized pivotal Phase 3 trial design for gedatolisib - Received FDA Fast Track designation for gedatolisib in HR+/HER2- advanced breast... 
From Celcuity Inc.
Via AccessWire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.